Time for transparency in drug pricing

From expert sources and recent data updates to a look at cases amid the ongoing respiratory virus season, this is an updated look at 2026 measles outbreaks in the US.

Zaid Fadul, MD, FS, FAAFP, joins for part 2 to discuss what greater adoption of AI across health care ecosystems might mean for pharmacists, patients, and more.

For pharmacies competing with CVS and relying on Caremark to serve patients, the prospect of those businesses operating under separate ownership is significant.

Erin Albert of Mark Cuban Cost Plus Drugs explains how the Team Cuban Card offers transparent pricing and fair pay for independent pharmacies.

An abstract from the American Heart Association's Scientific Sessions 2026 reveals the continuous expansion of the GLP-1 medication class.

Matthew Crawford, PhD, of the University of Virginia, and Mario Danek of Qnovia explain what pharmacists can do now and what may come next.

The inquiry puts audit practices, including how pharmacies are selected for audit, proportionality, and pharmacy advocacy in focus.

Nolla Derm’s overseeing physician, Zaid Fadul, MD, FS, FAAFP, discusses the revolutionary AI technology that could transform how health care conducts prescribing practices.